Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00276068 · ClinicalTrials.gov registry record · NA

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

A NA study, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
128
Enrollment target

NCT00276068 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 128 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00276068, a NA study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
128 participants
Enrollment target

Study Summary

The Vulvar Vestibulitis Clinical Trial (VVCT) a randomized, placebo-controlled, double blinded clinical trial. We will study the clinical efficacy of four medical treatments for vulvar vestibulitis: topical lidocaine, oral desipramine, combined lidocaine and desipramine, and placebo cream and capsules. Desipramine is a tricyclic antidepressant commonly used by clinicians for treatment of several chronic pain conditions that demonstrates an optimal side effect profile compared to other tricyclic antidepressants. Topical lidocaine has also been found to be beneficial for vulvar vestibulitis treatment in small studies. It is hypothesized that the combined use of oral desipramine and topical lidocaine will be more therapeutically effective than either one by itself and better than placebo.

Interventions

  • DRUG topical lidocaine + oral desipramine, and/or placebo

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2002-08
Est. Completion 2007-09
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00276068

The ClinicalTrials.gov registry entry for NCT00276068 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which topical lidocaine + oral desipramine, and/or placebo is the first listed.

NCT00276068 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00276068 about?

NCT00276068 is a clinical study titled "Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine". The Vulvar Vestibulitis Clinical Trial (VVCT) a randomized, placebo-controlled, double blinded clinical trial. We will study the clinical efficacy of four medical treatments for vulvar vestibulitis: topical lidocaine, oral desipramine, combined lidocaine and desipramine, and placebo cream and capsul...

What is the current status of trial NCT00276068?

This trial is currently completed. It is a NA study. The enrollment target is 128 participants. The study started on 2002-08. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00276068?

The interventions under investigation include: topical lidocaine + oral desipramine, and/or placebo (DRUG).

Who is sponsoring clinical trial NCT00276068?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.